 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.220.474 |
| Chemical and physical data | |
| Formula | C18H23NO3S |
| Molar mass | 333.45 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Ciglitazone (INN) is athiazolidinedione. Developed byTakeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.[1][2][3][4]
Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Severalanalogues were later developed, some of which—such aspioglitazone andtroglitazone—made it to the market.[2]
Ciglitazone significantly decreasesVEGF production by humangranulosa cells in an in vitro study, and may potentially be used inovarian hyperstimulation syndrome.[5]Ciglitazone is a potent and selectivePPARγ ligand. It binds to the PPARγ ligand-binding domain with anEC50 of 3.0 μM. Ciglitazone is active in vivo as an anti-hyperglycemic agent in the ob/ob murine model.[6] InhibitsHUVEC differentiation and angiogenesis and also stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.[7]
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |